Relmada Therapeutics (RLMD) Stock Forecast, Price Target & Predictions
RLMD Stock Forecast
Relmada Therapeutics stock forecast is as follows: an average price target of $5.67 (represents a 106.18% upside from RLMD’s last price of $2.75) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
RLMD Price Target
The average price target for Relmada Therapeutics (RLMD) is $5.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $2.00. This represents a potential 106.18% upside from RLMD's last price of $2.75.
RLMD Analyst Ratings
According to 2 Wall Street analysts, Relmada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Relmada Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $2.00 | $2.95 | -32.20% | -27.27% |
| Oct 13, 2022 | Andrew Tsai | Jefferies | $8.00 | $6.47 | 23.55% | 190.91% |
| Oct 13, 2022 | Jay Olson | Oppenheimer | $7.00 | $6.75 | 3.73% | 154.55% |
The latest Relmada Therapeutics stock forecast, released on Jun 05, 2024 by Andrea Tan from Goldman Sachs, set a price target of $2.00, which represents a -32.20% decrease from the stock price at the time of the forecast ($2.95), and a -27.27% decrease from RLMD last price ($2.75).
Relmada Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $2.75 | $2.75 | $2.75 |
| Upside/Downside | -100.00% | -100.00% | -27.27% |
In the current month, the average price target of Relmada Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relmada Therapeutics's last price of $2.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Jefferies | - | Buy | Upgrade |
| Jun 05, 2024 | Goldman Sachs | - | Sell | Downgrade |
| Oct 13, 2022 | Oppenheimer | - | Perform | Downgrade |
Relmada Therapeutics's last stock rating was published by Jefferies on Sep 16, 2024. The company Upgrade its RLMD rating from "null" to "Buy".
Relmada Therapeutics Financial Forecast
Relmada Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RLMD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Relmada Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict RLMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Relmada Therapeutics's previous annual EBITDA (undefined) of $NaN.
Relmada Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-16.60M | $-15.09M | $-14.48M | $-15.69M | $-20.59M | $-20.37M | $-24.97M |
| High Forecast | $-16.60M | $-15.09M | $-14.48M | $-15.69M | $-19.47M | $-20.37M | $-24.97M |
| Low Forecast | $-16.60M | $-15.09M | $-14.48M | $-15.69M | $-21.34M | $-20.37M | $-24.97M |
| Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RLMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Relmada Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RLMD last annual SG&A of $NaN (undefined).
Relmada Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.55 | $-0.50 | $-0.48 | $-0.52 | $-0.68 | $-0.68 | $-0.83 |
| High Forecast | $-0.55 | $-0.50 | $-0.48 | $-0.52 | $-0.65 | $-0.68 | $-0.83 |
| Low Forecast | $-0.55 | $-0.50 | $-0.48 | $-0.52 | $-0.71 | $-0.68 | $-0.83 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Relmada Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RLMD previous annual EPS of $NaN (undefined).
Relmada Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $1.05 | $30.71 | 2824.76% | Hold |
| IPSC | Century Therapeutics | $1.24 | $15.00 | 1109.68% | Buy |
| STTK | Shattuck Labs | $1.01 | $12.00 | 1088.12% | Hold |
| PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
| BCYC | Bicycle Therapeutics | $20.26 | $54.40 | 168.51% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
| RLMD | Relmada Therapeutics | $2.75 | $5.67 | 106.18% | Buy |
| NAMS | NewAmsterdam Pharma Company | $20.12 | $36.50 | 81.41% | Buy |
| CYTK | Cytokinetics | $47.67 | $83.23 | 74.60% | Buy |
| DYN | Dyne Therapeutics | $29.73 | $43.88 | 47.60% | Buy |
| THRD | Third Harmonic Bio | $11.45 | $16.15 | 41.05% | Buy |
| EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $56.78 | $60.63 | 6.78% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| FUSN | Fusion Pharmaceuticals | $21.55 | $15.25 | -29.23% | Hold |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |